for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Panacea Biotec Limited

PNCA.NS

Latest Trade

206.00INR

Change

5.55(+2.77%)

Volume

199,512

Today's Range

202.00

 - 

212.00

52 Week Range

85.95

 - 

263.35

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
200.45
Open
204.60
Volume
199,512
3M AVG Volume
3.29
Today's High
212.00
Today's Low
202.00
52 Week High
263.35
52 Week Low
85.95
Shares Out (MIL)
61.25
Market Cap (MIL)
12,277.71
Forward P/E
--
Dividend (Yield %)
--

Next Event

Panacea Biotec Ltd Annual Shareholders Meeting

Latest Developments

More

Panacea Biotec Posts Smaller Loss in Sept-Quarter

India's Panacea Biotec Completes Phase I/II Study Of Dengue Vaccine Candidate

Panacea Biotec June Quarter Consol Loss Widens

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Panacea Biotec Limited

Panacea Biotec Limited is a health management company. The Company's principal business activity is the manufacture of allopathic pharmaceuticals preparations. The Company's segments include Vaccines, Formulations, Research and Development; Healthcare and Real estate activities. Its Vaccines, Formulations and Research & Development segments are engaged in the business of research, development, manufacture and marketing of vaccines and branded pharmaceutical formulations. It has products for various segments, which include pediatric vaccines, pain management, diabetes management and organ transplantation. Its Healthcare segment is engaged in business of operating and maintaining hospitals. Its Real estate activities segment is engaged in the business of acquisition, construction and development of housing and commercial real estate projects. The Company's product portfolio includes prescription products in therapeutic areas, such as oncology, and nephrology and transplant management.

Industry

Biotechnology & Drugs

Contact Info

B-1 Extn / G-3

Mathura Road, Mohan Co-opIndlEstate

110044

India

+91.11.41679000

https://www.panaceabiotec.com/

Executive Leadership

Soshil Kumar Jain

Whole-Time Chairman of the Board

Devender Gupta

Chief Financial Officer

Vinod Goel

Compliance Officer, Company Secretary, General Manager - Legal

Rajesh Jain

Managing Director, Executive Director

Sandeep Jain

Joint Managing Director, Executive Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
2.02
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-16.33
Return on Equity (TTM)
-10.93

Latest News

Latest News

Panacea Biotec aims to make 1 bln doses of COVID-19 vaccine candidate in 2022

Indian biotech firm Panacea Biotec Ltd said on Wednesday it remains on schedule to produce first production quantities of COVID-19 vaccine candidate by January 2021.

Panacea Biotec sees production of 1 bln doses of COVID-19 vaccine candidate in 2022

Indian biotech firm Panacea Biotec Ltd said on Wednesday it remains on schedule to produce first production quantities of COVID-19 vaccine candidate by January 2021.

BRIEF-Panacea Biotec March-Quarter Consol Loss Narrows

* MARCH-QUARTER CONSOL NET LOSS 13.1 MILLION RUPEES VERSUS LOSS 64.3 MILLION RUPEES

BRIEF-Panacea Biotec Says Refana To Have Option To Invest $10 Mln In Co Under MoU

* REFANA TO HAVE OPTION TO INVEST $10 MILLION IN CO UNDER MOU Source text for Eikon: Further company coverage:

Indian firm Panacea says aiming to make COVID-19 vaccine

Indian biotech firm Panacea Biotec Ltd said on Wednesday it would partner with U.S.-based Refana Inc to make a potential vaccine for COVID-19.

BRIEF-Panacea Biotec Postpones EGM

* EGM HAS BEEN POSTPONED, RESCHEDULED TO BE HELD AFTER 31ST MARCH Source text for Eikon: Further company coverage:

BRIEF-India's Panacea Biotec Dec Qtr Consol Net Loss After Tax From Continuing Operations Widens

* DEC QUARTER CONSOL NET LOSS AFTER TAX FROM CONTINUING OPERATIONS 201.4 MILLION RUPEES VERSUS LOSS OF 138.7 MILLION RUPEES YEAR AGO

BUZZ-India's Panacea Biotec surges as IndiaRF will invest up to $144 mln in co

** Shares of health management company Panacea Biotec Ltd rise as much as 18.7 pct to 212.8 rupees, their biggest intraday gain since March 28, 2019

BUZZ-India's Panacea Biotec rises on settlement deal with Celgene

** Shares of Panacea Biotec Ltd rise as much as 5.2 pct to 287.2 rupees - highest since June 12

BRIEF-India's Panacea Biotec Gets EIR From U.S. FDA For Malpur Facility

* GETS ESTABLISHMENT INSPECTION REPORT INDICATING FORMAL CLOSURE OF INSPECTION AT PHARMACEUTICAL FORMULATION FACILITY AT MALPUR

BRIEF-India's Panacea Biotec MD Ravinder Jain Passes Away

* MD RAVINDER JAIN PASSES AWAY Source text - http://bit.ly/2sLxQk2 Further company coverage:

BRIEF-India's Panacea Biotec Dec Qtr Loss Narrows

* DEC QUARTER NET LOSS 97.1 MILLION RUPEES VERSUS LOSS 254.2 MILLION RUPEES YEAR AGO

BRIEF-Panacea Biotec Signs Agreements With Serum Institute Of India And Bilthovan Biologicals B V

* SAYS SIGNED TWO LONG AGREEMENTS WITH SERUM INSTITUTE OF INDIA AND BILTHOVAN BIOLOGICALS B V Source text: http://bit.ly/2ESdxT8 Further company coverage:

BRIEF-Panacea Biotec Says U.S. FDA Accepts Co's Marketing Application For Generic Cancer Drug

* SAYS U.S. FDA ACCEPTS CO'S ANDA FOR PACLITAXEL PROTEIN BOUND PARTICLES Source text: http://bit.ly/2BnVN02 Further company coverage:

BRIEF-India's Panacea Biotec Sept-qtr loss widens

* Sept quarter net loss 56.3 million rupees versus loss 49.5 million rupees year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up